Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesGemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas
Cancer, 06/01/09
Cassier PA et al. – Gemcitabine-oxaliplatin combination (GEMOX) is active and well tolerated in pretreated pts with metastatic neuroendocrine tumors.
Methods- Study of GEMOX efficacy in treatment of pts with metastatic neuroendocrine tumors
- GEMOX treatment for 20 consecutive pts with progressive disease, most cases after failure of other chemotherapy regimens (median 2 regimens)
- Follow-up for evidence of toxicity, response, and survival
- Exclusion from efficacy analysis of 2 pts chemotherapy-naive at treatment initiation
- Toxicity manageable overall
- Treatment discontinuation due to oxaliplatin-induced neurotoxicity (grade 2) in 6 pts (30%)
- Partial response for 3 (17%) of 18 pts
- Median progression-free survival: 7 mo
- Median overall survival: 23.4 mo
Related Articles
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Relevance Score: 95%
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Journal of Clinical Oncology, 11/13/09
Relevance Score: 93%
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Relevance Score: 93%
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
British Journal of Cancer, 11/18/09
Relevance Score: 91%
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09
Relevance Score: 91%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/18/09
Taurolidine in the prevention and therapy of lung metastases
European Journal of Cardio-Thoracic Surgery, 12/18/09
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Semi-Mechanistic Population Pharmacokinetic Drug-Drug Interaction Modelling of a Long Half-Life Substrate and Itraconazole
Clinical Pharmacokinetics, 12/18/09
Acetazolamide and midazolam act synergistically to inhibit neuropathic pain
Pain, 12/16/09
Cyclosporine Versus Tacrolimus in Immunosuppressive Maintenance Regimens in Renal Transplants in Brazil: Survival Analysis from 2000 to 2004
Annals of Pharmacotherapy, 12/16/09
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Modafinil for multiple sclerosis fatigue: Does it work
Clinical Neurology and Neurosurgery, 12/18/09
Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry in six countries
Current Medical Research and Opinion, 12/18/09
Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders
Phytotherapy Research, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor